氨磺必利与利培酮治疗精神分裂症对照研究

A control study of amisulpride vs .risperidone in the treatment of schizophrenia

目的：探讨氨磺必利与利培酮治疗精神分裂症的临床疗效和安全性。方法将60例精神分裂症患者随机分为两组，每组30例，研究组口服氨磺必利治疗，对照组口服利培酮治疗，观察8周。采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前呈持续性下降（P＜0．01），治疗各时段两组评分比较差异均无显著性（ P＞0．05）；治疗8周末研究组显效率60．0％、有效率83．3％，对照组分别为66．7％、86．7％，两组比较差异无显著性（χ2＝0．29、0．13，P＞0．05）。两组不良反应发生率比较差异均无显著性（P＞0．05）。结论氨磺必利治疗精神分裂症的疗效与利培酮相当，安全性高，依从性好。

Objective To explore the efficacy and safety of amisulpride vs .risperidone in the treatment of schizophrenia .Methods Sixty schizophrenics were randomly assigned to two groups of 30 ones each ,re-search group took orally amisulpride and control group did risperidone for 8 weeks .Efficacies were as-sessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results After treatment the total and each factor score of the PANSS of both groups lowered continuously compared with pretreatment （P〈 0 .01） ,there were no significant group differences in the PANSS scores in each period （P〉0 .05）;at the end of the 8th week obvious effec-tive and effective rate were respectively 60 .0% and 83 .3% in research and 66 .7% and 86 .7% in control group ,which showed no significant differences （χ2 = 0 .29 ,0 .13 ,P〉 0 .05） .There were no significant group differences in incidences of adverse reactions （P〉0 .05） .Conclusion Amisulpride has an efficacy equivalent to risperidone ,higher safety and better compliance in the treatment of schizophrenia .